98%
921
2 minutes
20
Introduction: The research into cardiac tumors can be traced back to the 18th century, when Bonet first introduced the relevant concept. It was not until 1936 that the first successful resection of a cardiac tumor was performed. From a pathological origin perspective, cardiac tumors can be categorized into two main types: primary tumors, which originate from the heart itself, and secondary tumors, which result from metastases of malignant tumors in other tissues or organs. Primary cardiac tumors are exceedingly rare, among primary cardiac tumors, roughly 75% are benign, while the remainder are malignant. In contrast, approximately 75% of primary malignant cardiac tumors are sarcomas. Cardiac myxoid fibrosarcoma stands out as a particularly rare diagnosis in this domain.
Case Report: Case one: A 25-year-old man presented with chest pain and tightness. After initial treatment, his symptoms recurred and worsened. Imaging revealed a large mass in the left atrium obstructing the mitral valve. He underwent surgical resection of the tumor, thrombectomy, and tricuspid valvuloplasty. Pathology diagnosed myxoid fibrosarcoma. The patient was readmitted 7 months later with hemoptysis due to tumor recurrence and was lost to follow-up after symptomatic treatment. Case two: A 67-year-old woman was admitted with cough, chest tightness, and shortness of breath. Physical examination and imaging showed a mass in the left atrium causing mitral valve obstruction. She underwent surgical resection of the tumor. Pathology confirmed myxoid fibrosarcoma. After 6 months of follow-up, there was no tumor recurrence or metastasis.
Discussion: Myxoid fibrosarcoma located in the left atrium can lead to mitral valve obstruction, causing symptoms of mitral stenosis such as dyspnea, cough, hemoptysis, and reduced exercise tolerance. Surgery remains the primary treatment for primary left atrial malignant tumors. Once the diagnosis is confirmed, active surgical intervention should be performed to relieve blood flow obstruction, remove pericardial effusion, and alleviate cardiac compression, which can extend patients' lives in the short term and improve their quality of life. Despite advancements in diagnostic techniques and surgical methods, the prognosis for patients with cardiac tumors still depends on the histology and location of the tumor.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310503 | PMC |
http://dx.doi.org/10.3389/fonc.2025.1567625 | DOI Listing |
BMJ Case Rep
September 2025
Cardiology, JIPMER, Puducherry, India.
A left ventricular sub-mitral thrombus without an aneurysm is a previously unreported rare occurrence. We aim to bring attention to this finding in a case of colorectal adenocarcinoma.An early 60s-year-old female presented with bleeding per rectum, weight loss and fatigue and was found to have colorectal carcinoma with metastasis based on examination, imaging and biopsy findings.
View Article and Find Full Text PDFAim Search for subclinical manifestations of cardiotoxicity in cancer patients at high and very high risk of cardiotoxicity and evaluation of the effectiveness of drug primary prevention during the antitumor treatment. Material and methods The study included 150 cancer patients with a high and very high Mayo Clinic (USA) Cardiotoxicity Risk Score. The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine.
View Article and Find Full Text PDFExp Clin Transplant
August 2025
>From the University Clinic for Nephrology, Faculty of Medicine, Saints Cyril and Methodius University in Skopje, Skopje, North Macedonia.
Posttransplant lymphoproliferative disorders are a serious complication after solid-organ transplant, with a reported incidence from 2% to 20%. Plasma cell neoplasms in solid-organ transplants represent a rare but increasingly serious complication after solid-organ transplant. We report a case of plasmablastic myeloma, a very rare variant of multiple myeloma with aggressive course and poor prognosis.
View Article and Find Full Text PDFPLoS One
September 2025
Biobank of Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.
Heart failure (HF) and lung cancer (LC) often coexist, yet their shared molecular mechanisms are unclear. We analyzed transcriptome data from the NCBI Gene Expression Omnibus (GEO) database (GSE141910, GSE57338) to identify 346 HF‑related differentially expressed genes (DEGs), then combined weighted gene co-expression network analysis (WGCNA) pinpointed 70 hub candidates. Further screening of these 70 hub candidates in TCGA lung cancer cohorts via LASSO, Random Forest, and multivariate Cox regression suggested CYP4B1 as the only independent prognostic marker.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.